Table 1 Participant characteristics in the study
Disease | No. of samples | Age at registration mean (SD), y | Age at diagnosis mean (SD), y | ||
|---|---|---|---|---|---|
Total | Male | Female | |||
Case | |||||
LS-related cancers | |||||
Biliary tract cancer | 1036 | 662 | 374 | 70.1 (9.2) | 68.7 (9.5) |
Brain cancerc | 201 | 97 | 104 | 65.5 (13.5) | - |
Colorectal cancerb | 16,540 | 10,410 | 6130 | 68.4 (10.4) | 65.5 (10.7) |
Endometrial cancer | 2298 | - | 2298 | 60.6 (11.3) | 56.3 (11.0) |
Gastric cancerb | 12,972 | 9645 | 3327 | 69.1 (10) | 65.7 (10.5) |
Ovarian cancer | 1723 | - | 1723 | 58.0 (12.3) | 53.7 (12.2) |
Pancreatic cancerb | 1140 | 709 | 431 | 68.0 (9.8) | 67.1 (10.1) |
Ureteral cancerc | 59 | 42 | 17 | 72.9 (8.3) | - |
Non LS-related cancers with ≥ 100 cases | |||||
Bladder cancerc | 1134 | 976 | 158 | 73.0 (8.4) | - |
Breast cancer (female) | 11,652 | - | 11,652 | 60.9 (12.3) | 56.3 (12.2) |
Cervical cancer | 2554 | - | 2554 | 56.1 (14) | 49.7 (13.2) |
Esophageal cancer | 2487 | 2124 | 363 | 67.6 (8.5) | 65.2 (8.5) |
Head neck cancerc | 894 | 768 | 126 | 70.0 (9.6) | - |
Liver cancer | 4333 | 3218 | 1115 | 68.9 (9.1) | 67.3 (9.4) |
Lung cancer | 8258 | 5394 | 2864 | 68.7 (9.4) | 66.5 (9.6) |
Lymphomab | 2065 | 1167 | 898 | 64.0 (13.5) | 60.2 (14.8) |
Prostate cancer | 12,304 | 12,304 | - | 72.6 (7.4) | 70.2 (7.3) |
Renal cancer | 1414 | 1066 | 348 | 67.2 (10.6) | 61.3 (11.2) |
Skin cancerc | 333 | 207 | 126 | 71.8 (9.8) | - |
Thyroid cancerc | 735 | 202 | 533 | 65.5 (11.8) | - |
Non LS-related cancers with <100 cases | |||||
Bone cancerc | 81 | 44 | 37 | 65.1 (11.8) | - |
Sarcomac | 41 | 23 | 18 | 62.5 (16.5) | - |
Testicular cancerc | 79 | 79 | - | 58.4 (13.6) | - |
Patient total | |||||
Patients | 74,085 | 42,332 | 31,753 | 66.8 (11.3) | - |
Casesa | 84,333 | 49,137 | 35,196 | - | 63.8 (11.8) |
Control | 38,842 | 21,830 | 17,012 | 66.6 (11.5) | - |
Total | 112,927 | 64,162 | 48,765 | - | - |
